Skip to content

Jobs updated Oct 23, 6:25 AM CT

COMPANY

Appello Pharmaceuticals

HQ: Nashville, TN source · appellopharma.com ↗

Clinical Phase 2

Location: Nashville, TN · source · Jan 24, 2022

Profile checked Oct 10, 2026

Keywords: Parkinson Disease AP-472

1Trials (company is sponsor)

Timeline

Feb 25, 2026 Trial start Phase 2: A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations source ↗

Upcoming milestones

Sep 3, 2027 (ESTIMATED) · Phase 2 · A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations · NCT07432958

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT07432958	A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations	Phase 2	Recruiting	Feb 25, 2026	Sep 3, 2027 (estimated)